Agios Pharmaceuticals to Present at a Prestigious Healthcare Conference
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), renowned for its breakthroughs in cellular metabolism and innovative pyruvate kinase (PK) activation therapies, is gearing up for an important presentation at a prominent healthcare conference. The event will take place on June 9, where Agios will be sharing its insights and advancements aimed at addressing rare diseases. Scheduled for 8:40 a.m. ET, this presentation marks a significant opportunity for Agios to highlight its continual efforts in transforming patient care.
Accessible Webcast for Investors
For those interested in following Agios’s presentation, a live webcast will be available via the Investors section of the company’s website. This accessibility ensures that individuals can stay informed and engaged with the company’s updates. After the live event, the presentation will be archived on Agios's website for at least two weeks, allowing further opportunities for the public to catch up on the insights shared during the conference.
About Agios Pharmaceuticals
Agios Pharmaceuticals stands as a beacon of innovation focused on PK activation, with a mission to develop transformative therapies for patients affected by rare diseases. One of their notable achievements is the introduction of a pioneering pyruvate kinase (PK) activator specifically for adults experiencing PK deficiency. This groundbreaking therapy represents a significant advance in the treatment of this rare and debilitating hemolytic anemia, illustrating Agios's commitment to addressing unmet medical needs.
Agios's Expansive Clinical Pipeline
Agios is not only dedicated to existing therapies but is also actively advancing a robust clinical pipeline. Their investigational medicines are in various stages of development, targeting a range of conditions including alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, myelodysplastic syndromes (MDS)-associated anemia, and phenylketonuria (PKU). In addition, Agios is exploring a preclinical TMPRSS6 siRNA, which may offer a new treatment avenue for polycythemia vera.
Commitment to Patients
With a strong foundation in classical hematology and a focus on cellular metabolism, Agios Pharmaceuticals continues to pave the way for innovative solutions in the treatment of rare blood disorders. Their ongoing commitment to enhancing patient outcomes is reflected in their extensive research efforts and the development of new therapies.
Contact Information for Further Inquiries
For additional information and investor-related inquiries, Agios Pharmaceuticals has designated contacts ready to assist. Morgan Sanford, Vice President of Investor Relations, is available for any questions regarding the company's strategic initiatives and performance. Eamonn Nolan, Senior Director of Corporate Communications, is the go-to contact for media relations and inquiries.
Frequently Asked Questions
What will Agios Pharmaceuticals present at the conference?
Agios will share insights about its innovative therapies and advancements in treating rare diseases.
When is the presentation scheduled?
The presentation is set for June 9 at 8:40 a.m. ET.
How can I access the webcast?
The live webcast will be available on Agios's Investors page and will be archived for two weeks after the event.
What are some conditions Agios focuses on?
Agios concentrates on various rare conditions, including sickle cell disease and PK deficiency, among others.
Who can I contact for more information about Agios?
For investor inquiries, contact Morgan Sanford, and for media information, reach out to Eamonn Nolan.
